Published in Neurosci Lett on March 01, 2010
Oxidative genome damage and its repair: implications in aging and neurodegenerative diseases. Mech Ageing Dev (2012) 1.13
Oxidative genome damage and its repair in neurodegenerative diseases: function of transition metals as a double-edged sword. J Alzheimers Dis (2011) 1.13
Oxidized base damage and single-strand break repair in mammalian genomes: role of disordered regions and posttranslational modifications in early enzymes. Prog Mol Biol Transl Sci (2012) 0.87
Transcriptional mutagenesis by 8-oxodG in α-synuclein aggregation and the pathogenesis of Parkinson's disease. Exp Mol Med (2015) 0.80
An overview of DNA repair in amyotrophic lateral sclerosis. ScientificWorldJournal (2011) 0.80
Base excision repair in physiology and pathology of the central nervous system. Int J Mol Sci (2012) 0.78
Epidemiological, clinical, and molecular study of a cohort of Italian Parkinson disease patients: association with glutathione-S-transferase and DNA repair gene polymorphisms. Cell Mol Neurobiol (2013) 0.77
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (2008) 5.37
The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord (2009) 3.56
Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol (2007) 3.25
Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord (2004) 2.90
An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. Carcinogenesis (2006) 2.45
MR imaging of the substantia nigra at 7 T enables diagnosis of Parkinson disease. Radiology (2014) 2.14
Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature (2012) 2.08
Nerve, muscle and heart acute toxicity following oxaliplatin and capecitabine treatment. Neuromuscul Disord (2012) 2.01
Dopamine agonists and delusional jealousy in Parkinson's disease: a cross-sectional prevalence study. Mov Disord (2012) 1.98
Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. Arch Neurol (2008) 1.96
Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2010) 1.94
A two-stage genome-wide association study of sporadic amyotrophic lateral sclerosis. Hum Mol Genet (2009) 1.93
Diffusion-tensor MR imaging of corticospinal tract in amyotrophic lateral sclerosis and progressive muscular atrophy. Radiology (2005) 1.90
Large-scale population analysis challenges the current criteria for the molecular diagnosis of fascioscapulohumeral muscular dystrophy. Am J Hum Genet (2012) 1.88
Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord (2007) 1.85
Mutations of FUS gene in sporadic amyotrophic lateral sclerosis. J Med Genet (2009) 1.79
How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. Parkinsonism Relat Disord (2007) 1.72
Weight loss in combination with physical activity improves endothelial dysfunction in human obesity. Diabetes Care (2003) 1.72
Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians. Eur J Hum Genet (2005) 1.71
Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study. Mov Disord (2013) 1.62
Rippling muscle disease and facioscapulohumeral dystrophy-like phenotype in a patient carrying a heterozygous CAV3 T78M mutation and a D4Z4 partial deletion: Further evidence for "double trouble" overlapping syndromes. Neuromuscul Disord (2012) 1.59
Folate gene polymorphisms and the risk of Down syndrome pregnancies in young Italian women. Am J Med Genet A (2006) 1.58
Phenotypic heterogeneity of the 8344A>G mtDNA "MERRF" mutation. Neurology (2013) 1.55
Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: clinical and biological results from a prospective multicenter study. Muscle Nerve (2011) 1.54
Association between amantadine and the onset of dementia in Parkinson's disease. Mov Disord (2006) 1.50
Genetics, cytogenetics, and epigenetics of colorectal cancer. J Biomed Biotechnol (2011) 1.50
Subclinical cardiac involvement in patients with facioscapulohumeral muscular dystrophy. Neuromuscul Disord (2005) 1.48
The arginine growth hormone stimulation test in bradykinetic-rigid parkinsonisms. Mov Disord (2008) 1.43
Affective theory of mind in patients with Parkinson's disease. Psychiatry Clin Neurosci (2013) 1.41
Diagnosis, assessment and management of delusional jealousy in Parkinson's disease with and without dementia. Neurol Sci (2012) 1.39
[Mechanism of troponin and CK-MB release after percutaneous coronary interventions]. Ital Heart J Suppl (2002) 1.39
Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. Neurobiol Aging (2002) 1.35
The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. J Neurol (2012) 1.34
SOD1 mutations in amyotrophic lateral sclerosis. Results from a multicenter Italian study. J Neurol (2005) 1.30
Mitochondria and neurodegeneration. Biosci Rep (2007) 1.22
Mitochondrial dysfunction, oxidative stress and neurodegeneration. J Alzheimers Dis (2006) 1.20
Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson's disease. J Neurol Neurosurg Psychiatry (2012) 1.20
Clinical features associated with ictal osmophobia in migraine. Neurol Sci (2014) 1.19
The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a meta-analysis study. J Alzheimers Dis (2010) 1.19
Pleiotropic effects of spastin on neurite growth depending on expression levels. J Neurochem (2009) 1.18
Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst (2006) 1.15
A standardized clinical evaluation of patients affected by facioscapulohumeral muscular dystrophy: The FSHD clinical score. Muscle Nerve (2010) 1.15
A molecular signature in blood identifies early Parkinson's disease. Mol Neurodegener (2012) 1.13
Genes and the environment in neurodegeneration. Biosci Rep (2006) 1.11
Concern-driven integrated approaches to nanomaterial testing and assessment--report of the NanoSafety Cluster Working Group 10. Nanotoxicology (2013) 1.10
A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica (2011) 1.10
The m.3243A>G mitochondrial DNA mutation and related phenotypes. A matter of gender? J Neurol (2013) 1.09
Impulsivity and compulsivity in drug-naïve patients with Parkinson's disease. Mov Disord (2011) 1.08
Next-generation sequencing identifies transportin 3 as the causative gene for LGMD1F. PLoS One (2013) 1.07
Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. J Neurol (2009) 1.05
Proton MR spectroscopy of mitochondrial diseases: analysis of brain metabolic abnormalities and their possible diagnostic relevance. AJNR Am J Neuroradiol (2003) 1.05
POLG1-related and other "mitochondrial Parkinsonisms": an overview. J Mol Neurosci (2011) 1.05
Large scale genotype-phenotype analyses indicate that novel prognostic tools are required for families with facioscapulohumeral muscular dystrophy. Brain (2013) 1.05
Mild cognitive impairment and cognitive reserve in Parkinson's disease. Parkinsonism Relat Disord (2011) 1.04
Could mitochondrial haplogroups play a role in sporadic amyotrophic lateral sclerosis? Neurosci Lett (2004) 1.04
Non-motor functions in parkinsonian patients implanted in the pedunculopontine nucleus: focus on sleep and cognitive domains. J Neurol Sci (2009) 1.04
Changes in pattern electroretinograms to equiluminant red-green and blue-yellow gratings in patients with early Parkinson's disease. J Clin Neurophysiol (2003) 1.03
Phenotype modulators in myophosphorylase deficiency. Ann Neurol (2003) 1.02
DNA damage and repair in Alzheimer's disease. Curr Alzheimer Res (2009) 1.02
Coenzyme Q10 is frequently reduced in muscle of patients with mitochondrial myopathy. Neuromuscul Disord (2009) 1.01
Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations. Neurobiol Aging (2011) 1.00
Dopaminergic modulation of visual-spatial working memory in Parkinson's disease. Dement Geriatr Cogn Disord (2003) 1.00
A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis. Hum Mol Genet (2013) 0.98
Redefining phenotypes associated with mitochondrial DNA single deletion. J Neurol (2015) 0.98
IGF1 as a Potential Treatment for Rett Syndrome: Safety Assessment in Six Rett Patients. Autism Res Treat (2012) 0.97
Genotoxic and epigenetic mechanisms in arsenic carcinogenicity. Arch Toxicol (2014) 0.97
Personality traits in patients with Parkinson's disease: assessment and clinical implications. J Neurol (2011) 0.96
Clinical and molecular characterization of patients with limb-girdle muscular dystrophy type 2I. Arch Neurol (2005) 0.96
A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice. Clin Neuropharmacol (2012) 0.96
Oxidative stress biomarkers in mitochondrial myopathies, basally and after cysteine donor supplementation. J Neurol (2009) 0.96
Comparison study of MS-HRM and pyrosequencing techniques for quantification of APC and CDKN2A gene methylation. PLoS One (2013) 0.95
The role of mitochondria in stem cell biology. Biosci Rep (2007) 0.95
Epigenetic effects of nano-sized materials. Toxicology (2012) 0.94
Decreased platelet cytochrome c oxidase activity is accompanied by increased blood lactate concentration during exercise in patients with Alzheimer disease. Exp Neurol (2003) 0.94
Theory of Mind in Parkinson's disease. Behav Brain Res (2011) 0.94
DNA repair in premature aging disorders and neurodegeneration. Curr Aging Sci (2010) 0.94
Orthostatic hypotension in de novo Parkinson disease. Arch Neurol (2003) 0.94
Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management. Parkinsonism Relat Disord (2009) 0.94
Anemia and iron overload due to compound heterozygosity for novel ceruloplasmin mutations. Blood (2002) 0.93
Obesity and diabetes: from genetics to epigenetics. Mol Biol Rep (2015) 0.92
Decision making in de novo Parkinson's disease. Mov Disord (2010) 0.92